Corporate & Investor Presentation
Q4 FY20 financial results
Diversified revenue
by business & by geography
OOH SaaS
12%
*
$ in millions, except per share amounts
Revenue
Non-GAAP gross margin
Non-GAAP operating income*
Non-GAAP EPS*
4Q20
$770.3
+9% (+10% CC)
59.9%
+60 bps
$243.4
+24%
$1.33
+40%
ResMed adjusts for the impact of the amortization of acquired intangibles, deferred revenue fair value adjustment, fair
value impairment of investments, and the impact of U.S. tax reform on income tax expense from their evaluation of
ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful
evaluation of current operating performance.
Masks & Other
35%
Europe, Asia,
and Other
36%
35 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20
U.S. SaaS
12%
Devices
53%
Americas Sleep and
Respiratory Care
52%
ResMedView entire presentation